TY - JOUR
T1 - Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation
AU - on behalf of the transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation
AU - Harada, Kaito
AU - Fuji, Shigeo
AU - Seo, Sachiko
AU - Kanda, Junya
AU - Ueki, Toshimitsu
AU - Kimura, Fumihiko
AU - Kato, Koji
AU - Uchida, Naoyuki
AU - Ikegame, Kazuhiro
AU - Onizuka, Makoto
AU - Matsuoka, Ken ichi
AU - Doki, Noriko
AU - Kawakita, Toshiro
AU - Onishi, Yasushi
AU - Yano, Shingo
AU - Fukuda, Takahiro
AU - Takanashi, Minoko
AU - Kanda, Yoshinobu
AU - Atsuta, Yoshiko
AU - Ogata, Masao
AU - Harada, Kaito
AU - Fuji, Shigeo
AU - Seo, Sachiko
AU - Ueki, Toshimitsu
AU - Ogata, Masao
N1 - Funding Information:
Acknowledgements We thank all the physicians and staff at the transplant centers who provided the clinical data to the Transplant Registry Unified Management Program of the Japan Society of Hematopoietic Cell Transplantation. This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED under Grant Number 18ek0510023h0002.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.
AB - Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.
UR - http://www.scopus.com/inward/record.url?scp=85079709012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079709012&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-0821-9
DO - 10.1038/s41409-020-0821-9
M3 - Article
C2 - 32051535
AN - SCOPUS:85079709012
SN - 0268-3369
VL - 55
SP - 1784
EP - 1795
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 9
ER -